Compounders Research Compare

Lakewood-Amedex Biotherapeutics, Inc.(LABT)

Biotechnology · University Park, FL

$0.87+0.01 (+1.42%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

University Park, FL

5 employees

www.lakewoodamedex.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Kelvin Cooper

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T22:51:46.826Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:51:46.826Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,517,820
Total debt · period ending 2026-06-30: 101,619
Cash · period ending 2026-06-30: 2,584,774
TTM free cash flow · period ending 2026-06-30: -3,485,776

FMP input reference: f3e61b787222715dff3a983a87307d60b14e7521dca9159fec0ee57fbd3bd529

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

LABT EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

LABT Competitors' EV/FCF Ratio

Lakewood-Amedex Biotherapeutics, Inc.

Current

Market Cap

$1.52M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PMGC Holdings Inc.

Market Cap

$1.49M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NEXGEL, Inc.

Market Cap

$1.47M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Curis, Inc.

Market Cap

$1.46M

EV/FCF Ratio

N/A

TTM Avg

56.09x

3Y Avg

56.09x

5Y Avg

56.09x

INVO Fertility, Inc.

Market Cap

$1.42M

EV/FCF Ratio

N/A

TTM Avg

7.22x

3Y Avg

7.22x

5Y Avg

7.22x

Silo Pharma, Inc.

Market Cap

$1.64M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Jupiter Neurosciences, Inc.

Market Cap

$1.39M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Artelo Biosciences, Inc.

Market Cap

$1.34M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NewcelX Ltd.

Market Cap

$1.33M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Genprex, Inc.

Market Cap

$1.32M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Lakewood-Amedex Biotherapeutics, Inc. (LABT)	$1.52M	N/A	N/A	N/A	N/A
PMGC Holdings Inc. (ELAB)vs ›	$1.49M	N/A	N/A	N/A	N/A
NEXGEL, Inc. (NXGL)vs ›	$1.47M	N/A	N/A	N/A	N/A
Curis, Inc. (CRIS)vs ›	$1.46M	N/A	56.09x	56.09x	56.09x
INVO Fertility, Inc. (IVF)vs ›	$1.42M	N/A	7.22x	7.22x	7.22x
Silo Pharma, Inc. (SILO)vs ›	$1.64M	N/A	N/A	N/A	N/A
Jupiter Neurosciences, Inc. (JUNS)vs ›	$1.39M	N/A	N/A	N/A	N/A
Artelo Biosciences, Inc. (ARTL)vs ›	$1.34M	N/A	N/A	N/A	N/A
NewcelX Ltd. (NCEL)vs ›	$1.33M	N/A	N/A	N/A	N/A
Genprex, Inc. (GNPX)vs ›	$1.32M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics